BIIB Latest Headlines

Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long-Term Growth

at www.tipranks.com (Fri, 5-Jun 12:34 PM)

Biogen Expands Rare Disease Portfolio with Apellis Acquisition—Key Growth Drivers Unveiled

Market Chameleon (Thu, 14-May 11:35 AM)

Biogen’s Diranersen Shows First Evidence of Tau Reduction and Cognitive Benefit in Early Alzheimer’s—Key Phase 2 Details Revealed

Market Chameleon (Thu, 14-May 7:31 AM)

Biogen’s $5.6 Billion Apellis Acquisition Adds Growth Engines in Rare Disease, Immunology, and Nephrology

Market Chameleon (Tue, 31-Mar 8:37 AM)